{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335106","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2026-08-05T20:10:20+00:00","discovered_at":"2026-08-05T20:12:30.200370+00:00","generated_at":"2026-08-05T20:13:12.826457+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Standard BioTools Q2 revenue $20.1M, down 7.6% YoY; adjusted EBITDA improves 84%","bullets":["Revenue $20.1M, down 7.6% YoY; consumables $9.4M (-10%), instruments $5.1M (-2%), services $5.6M (-8%).","Net loss from continuing ops $21.5M vs $17.7M; operating loss $25.4M vs $25.7M.","Adjusted EBITDA loss $2.5M, improvement of $13.6M or 84% YoY.","Merger with Treeline Biosciences progressing; stockholder vote expected before year-end 2026.","Withdrew full year 2026 revenue outlook due to pending merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335106","json":"https://secwatch.observer/filing/0001193125-26-335106.json","markdown":"https://secwatch.observer/filing/0001193125-26-335106.md","text":"https://secwatch.observer/filing/0001193125-26-335106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/0001193125-26-335106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526335106/lab-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:13:12.826457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}